Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $90.93 Consensus Target Price from Brokerages
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12-month target price […]
More Stories
Air Transat Pilots Issue Strike Notice, Causing Flight Suspensions
By Olivia Gomm The union representing Air Transat pilots has issued a 72-hour strike notice, saying that the pilots intend...
Dollar General Plans to Open 450 New Stores in US in 2026
By Rob Sabo Backed by strong third-quarter net sales of $10.6 billion, Dollar General on Dec. 4 said it plans...
Dr. Oz Threatens to Pull Funding From Minnesota After $1 Billion in Medicaid Funding Was Stolen by Fraudsters
By Jacki Thrapp The Centers for Medicare & Medicaid Services (CMS) threatened to withhold federal funding from Minnesota after fraudsters...
FBI Director Patel Provides Update on Charlie Kirk Assassination Investigation
By Jack Phillips FBI Director Kash Patel has provided an update on the investigation of the assassination of Charlie Kirk,...
Watchdog Uncovers Massive Fraud, Waste in Obamacare Insurance Tax Credits
By Naveen Athrappully An analysis of the Patient Protection and Affordable Care Act (PPACA), commonly known as Obamacare, has unveiled...
US Investor Home Purchases Stall in 3rd Quarter Amid Falling Flipping, Rental Profits
By Mary Prenon Investor home purchases saw little advancement in the third quarter of this year, with just a 1...